Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Anagrelide hydrochloride
Drug ID BADD_D00140
Description Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms.[L14153] It is an oral imidazoquinazoline that was first approved for use in the US in 1997.[A214274] It appears to carry a better response rate than other thrombocythemia treatments (e.g. [busulfan], [hydroxyurea]) and may be better tolerated.[A214274]
Indications and Usage For the treatment of patients with thrombocythemia, secondary to myeloproliferative disorders, to reduce the elevated platelet count and the risk of thrombosis and to ameliorate associated symptoms including thrombo-hemorrhagic events.
Marketing Status Prescription; Discontinued
ATC Code L01XX35
DrugBank ID DB00261
KEGG ID D02933
MeSH ID C021139
PubChem ID 135413494
TTD Drug ID D0D1HW
NDC Product Code 54092-063; 0172-5241; 53104-7537; 65841-106; 63552-005; 42571-413; 0172-5240; 63818-0425
Synonyms anagrelide | Agrylin | BL 4162A | Agrelin | anagrelide hydrochloride | imidazo(2,1-b)quinazolin-2(3H)-one, 6,7-dichloro-1,5-dihydro-, monohydrochloride | 6,7-dichloro-1,5-dihydroimidazo(2,1-b)quinazolin-2(3H)-one hydrochloride
Chemical Information
Molecular Formula C10H8Cl3N3O
CAS Registry Number 58579-51-4
SMILES C1C2=C(C=CC(=C2Cl)Cl)N=C3N1CC(=O)N3.Cl
Chemical Structure
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Dizziness02.01.02.004; 17.02.05.003; 24.06.02.007--
Dyspepsia07.01.02.001--
Dyspnoea02.01.03.002; 22.02.01.004--
Dysuria20.02.02.002--
Ecchymosis01.01.03.001; 23.06.01.001; 24.07.06.002--Not Available
Eosinophilic pneumonia01.02.04.003; 22.01.01.004--Not Available
Epistaxis22.04.03.001; 24.07.01.005--
Eructation07.01.02.003--
Fatigue08.01.01.002--
Flatulence07.01.04.002--
Gastritis07.08.02.001--
Gastrointestinal haemorrhage07.12.02.001; 24.07.02.009--Not Available
Haematuria20.02.01.006; 24.07.01.047--
Headache17.14.01.001--
Heart rate increased13.14.04.002--Not Available
Hepatotoxicity09.01.07.009; 12.03.01.008--Not Available
Hypertension24.08.02.001--
Hypoaesthesia17.02.06.023--Not Available
Influenza11.05.03.001; 22.07.02.001--Not Available
Insomnia17.15.03.002; 19.02.01.002--
Interstitial lung disease10.02.01.033; 22.01.02.003--Not Available
Lymphadenopathy01.09.01.002--Not Available
Malaise08.01.01.003--
Melaena07.12.02.004; 24.07.02.013--Not Available
Migraine17.14.02.001; 24.03.05.003--Not Available
Muscle spasms15.05.03.004--
Myalgia15.05.02.001--
Nausea07.01.07.001--
Nervousness19.06.02.003--Not Available
Oedema08.01.07.006; 14.05.06.010--Not Available
The 2th Page    First    Pre   2 3 4    Next   Last    Total 4 Pages